Mastocytosis is a heterogeneous group of hematopoietic disorders characterized by abnormal growth and accumulation of mast cells (MC) in one or more organs. Clinical symptoms occur as a result of the release of chemical mediators and/or of pathologic infiltration of MC in various tissues. Although the initial events leading to mastocytosis have not yet been unraveled, acquired alterations in the c-kit gene coding for the receptor of stem cell factor (SCF), a major cytokine involved in MC growth, have been described in a significant number of patients. Of particular interest are point mutations resulting in a constitutively activated SCF receptor. Such mutations are probably involved in the abnormal (SCF-independent) proliferation of MC in these patients. New therapeutic strategies may be envisaged to inhibit the deregulated kinase activity of these mutant forms of c-kit.

Keywords:
Mast cell, Mastocytosis, Stem cell factor, c-kit, Mutation
1.
Ishizaka T, Mitsui H, Yanagida M, Miura T, Dvorak AM: Development of human mast cells from their progenitors. Curr Opin Immunol 1993;937–943.
2.
Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD: Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood 1999;94:2333–2343.
3.
Irani AM, Nilsson G, Miettinen U, Craig SS, Ashman LK, Ishizaka T, Zsebo KM, Schwartz LB: Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells. Blood 1992;80:3009–3021.
4.
Boissan M, Feger F, Guillosson JJ, Arock M: c-Kit and c-kit mutations in mastocytosis and other hematological diseases. J Leukoc Biol 2000;67:135–148.
5.
Ashman LK: The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999;31:1037–1051.
6.
Lev S, Givol D, Yarden Y: Interkinase domain of kit contains the binding site for phosphatidylinositol 3′ kinase. Proc Natl Acad Sci USA 1992;89:678–682.
7.
Weiler SR, Mou S, DeBerry CS, Keller JR, Ruscetti FW, Ferris DK, Longo DL, Linnekin D: JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor. Blood 1996;87:3688–3693.
8.
Deberry C, Mou S, Linnekin D: Stat1 associates with c-kit and is activated in response to stem cell factor. Biochem J 1997;327:73–80.
9.
Linnekin D, DeBerry CS, Mou S: Lyn associated with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells. J Biol chem 1997;272:27450–27455.
10.
Linnekin D, Weiler SR, Mou S, DeBerry CS, Keller JR, Ruscetti FW, Ferris DK, Longo DL: JAK2 is constitutively associated with c-Kit and is phosphorylated in response to stem cell factor. Acta Haematol 1996;95:224–228.
11.
Taylor ML, Metcalfe DD: Kit signal transduction. Hematol Oncol Clin North Am 2000;14:517–535.
12.
Longley BJ, Reguera MJ, Ma Y: Classes of c-KIT activating mutations: Proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 2001;25:571–576.
13.
Pauls JD, Brems J, Pockros PJ, Saven A, Wagner RL, Weber R, Metcalfe D, Christiansen SC: Mastocytosis: Diverse presentations and outcomes. Arch Intern Med 1999;159:401–405.
14.
Horny HP, Ruck P, Krober S, Kaiserling E: Systemic mast cell disease (mastocytosis). General aspects and histopathological diagnosis. Histol Histopathol 1997;12:1081–1089.
15.
Valent P: Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr 1996;108:385–397.
16.
Longley J, Duffy TP, Kohn S: The mast cell and mast cell disease. J Am Acad Dermatol 1995;545–561; quiz 562–564.
17.
Metcalfe DD: Classification and diagnosis of mastocytosis: Current status. J Invest Dermatol 1991;96:2S–4S.
18.
Friedman BS, Metcalfe DD: Mastocytosis. Prog Clin Biol Res 1989;297:163–173.
19.
Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G, Nunez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW, Bennett JM: Diagnostic criteria and classification of mastocytosis: A consensus proposal. Leuk Res 2001;25:603–625.
20.
Costa J, Demetri G, Harrist T, Dvorak A, Hayes D, Merica E, Menchaca D, Gringeri A, Schwartz L, Galli S: Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 1996;193:2681–2686.
21.
Longley BJ Jr, Morganroth GS, Tyrrell L, Ding TG, Anderson DM, Williams DE, Halaban R: Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med 1993;238:1302–1307.
22.
Tsujimura T, Furitsu T, Morimoto M, Isozaki K, Nomura S, Matsuzawa Y, Kitamura Y, Kanakura Y: Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood 1994;83:2619–2626.
23.
Tsujimura T, Morimoto M, Hashimoto K, Moriyama Y, Kitayama H, Matsuzawa Y, Kitamura Y, Kanakura Y: Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain. Blood 1996;87:273–283.
24.
Tsujimura T, Furitsu T, Morimoto M, Kanayama Y, Nomura S, Matsuzawa Y, Kitamura Y, Kanakura Y: Substitution of an aspartic acid results in constitutive activation of c-kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int Arch Allergy Immunol 1995;106:377–385.
25.
Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, et al: Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:1736–1744.
26.
Tsujimura T, Kanakura Y, Kitamura Y: Mechanisms of constitutive activation of c-kit tyrosine kinase. Leukemia 1997;11(suppl 3):396–398.
27.
Ma Y, Cunningham ME, Wang X, Ghosh I, Regan L, Longley BJ: Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region. J Biol Chem 1999;274:13399–13402.
28.
Piao X, Bernstein A: A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood 1996;87:3117–3123.
29.
Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, Duffy T, Jacobs P, Tang LH, Modlin I: Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12:312–314.
30.
Buttner C, Henz BM, Welker P, Sepp NT, Grabbe J: Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: A possible explanation for divergent clinical behavior. J Invest Dermatol 1998;111:1227–1231.
31.
Sotlar K, Marafioti T, Griesser H, Theil J, Aepinus C, Jaussi R, Stein H, Valent P, Horny HP: Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol Pathol 2000;53:188–193.
32.
Longley BJ Jr, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, Heitjan D, Ma Y: Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999;96:1609–1614.
33.
Pullarkat VA, Pullarkat ST, Calverley DC, Brynes RK: Mast cell disease associated with acute myeloid leukemia: Detection of a new c-kit mutation Asp816His. Am J Hematol 2000;65:307–309.
34.
Pignon J, Giraudier S, Duquesnoy P, Jounault H, Imbert M, Vainchenker W, Vernant J, Tulliez M: A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol 1997;96:374–376.
35.
Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD: Analysis of the surface expression of c-kit and occurrence on the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 2000;28:140–147.
36.
Ma Y, Carter E, Wang X, Shu C, McMahon G, Longley BJ: Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells. J Invest Dermatol 2000;114:392–394.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.